Page 7,084«..1020..7,0837,0847,0857,086..7,0907,100..»

New device is more effective and safer than FDA-approved treatment for acute stroke patients

Posted: Published on February 27th, 2012

A new approach to stroke treatment initially developed by Dr. Jeffrey Saver's group at the UCLA Stroke Center combines the ability to restore circulation and remove clots using only a single device ... and it's showing significant promise in trials. In a study comparing the Covidien Solitaire FR Revascularization Device with the FDA-approved Merci Retriever, the device successfully and safely treated roughly 60 percent of stroke patients, compared to roughly 30 percent when the Merci Retriever was used. Such treatment is intended to minimize brain damage due to lack of oxygen and/or glucose in patients presenting with blockage of large intracranial blood vessels - particularly those for whom the use of clot-dissolving drugs is not advisable. The Solitaire Revascularization Device in use (Image: Covidien) Roughly speaking, there are four main steps in the operation: 1. Poke a hole in the clot with a microcatheter (roughly 2.5 mm/0.1-inch in diameter). 2. Slide the Solitaire device through the microcatheter until it extends on either side of the clot. 3. Slide the microcatheter back so that the Solitaire device expands and traps the clot. 4. Pull the Solitaire device back to the end of the microcatheter, and use suction to remove the clot … Continue reading →

Comments Off on New device is more effective and safer than FDA-approved treatment for acute stroke patients

Vernalis probes new Parkinson’s treatments

Posted: Published on February 27th, 2012

Cambridge pharma company Vernalis is collaborating with UK-based Britannia Pharmaceuticals to explore development of new formulations of apomorphine in North America for the treatment of Parkinson's disease. Britannia has granted Vernalis exclusive rights to use Britannia's technology to develop a continuous sub-cutaneous infusion of apomorphine in North America. This product is currently marketed in Europe by Britannia and can be used in patients with frequent fluctuations or who require multiple injections in a day. Terms have also been negotiated to develop a nasal powder formulation of apomorphine in North America. Britannia is currently conducting Phase II clinical trials with this formulation in Europe. Vernalis has also announced the acquisition of from US WorldMeds’ Apokyn® (apomorphine hydrochloride injection) which is indicated for the acute, intermittent treatment of ‘off’ episodes associated with Parkinson's. Simon Sturge, the Vernalis CEO, said “This agreement with Britannia complements our acquisition of Apokyn® and further strengthens our Parkinson's disease franchise.” Vernalis has also announced the successful completion of a long-term Phase III open-label safety study of frovatriptan administered for six days a month for 12 months in the prevention of migraine in patients with migraines related to their menstrual cycles. In total, 525 patients entered the study … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Vernalis probes new Parkinson’s treatments

TBI crisis: As evidence mounts of effects of brain injuries on children, financing lags and Congress considers a bill

Posted: Published on February 27th, 2012

Patrick Donohue has been doing the math, but he can't get it to add up: Brain injury is the biggest cause of death and disabilities for kids and young adults by a large margin, sending more than 765,000 young Americans to the emergency room every year. So why, he wonders, does funding for it lag so far behind most everything? Other numbers puzzle him, too. Like this one: Why can 10 trips to 10 doctors yield 10 different treatment plans if so many kids — and adults, too — have brain injuries? He describes treatment as frequently "arbitrary and random." Donohue has become an expert on traumatic brain injury, something he never knew much about until the baby nurse he and his wife hired to help when his daughter Sarah Jane was born instead shook her when she was 5 days old, resulting in four broken ribs, two broken collarbones and severe brain damage. Six years later, Donohue figures his job "is to change the world for her. She walks with assistance. She can't do any of those functions by herself." So he uses the experience from what seems like a former life as a political consultant to raise money … Continue reading →

Posted in Brain Injury Treatment | Comments Off on TBI crisis: As evidence mounts of effects of brain injuries on children, financing lags and Congress considers a bill

As evidence mounts on effects of brain injuries on children, financing lags

Posted: Published on February 27th, 2012

Patrick Donohue has been doing the math, but he can't get it to add up: Brain injury is the biggest cause of death and disabilities for kids and young adults by a large margin, sending more than 765,000 young Americans to the emergency room every year. So why, he wonders, does funding for it lag so far behind most everything? Other numbers puzzle him, too. Like this one: Why can 10 trips to 10 doctors yield 10 different treatment plans if so many kids — and adults, too — have brain injuries? He describes treatment as frequently "arbitrary and random." Donohue has become an expert on traumatic brain injury, something he never knew much about until the baby nurse he and his wife hired to help when his daughter Sarah Jane was born instead shook her when she was 5 days old, resulting in four broken ribs, two broken collarbones and severe brain damage. Six years later, Donohue figures his job "is to change the world for her. She walks with assistance. She can't do any of those functions by herself." So he uses the experience from what seems like a former life as a political consultant to raise money … Continue reading →

Posted in Brain Injury Treatment | Comments Off on As evidence mounts on effects of brain injuries on children, financing lags

Steven Strauss: Chelsea Clinton for Congress? What Does That Tell Us About America?

Posted: Published on February 27th, 2012

HuffPost's QuickRead... Loading... HuffPost's QuickRead... EDITION: U.S. CA Canada  Québec FR France US United States UK United Kingdom Haley Barbour Elections 2012 Smarter Ideas More Log in | Create Account | Sign Out February 27, 2012 Like 112k   CONNECT     FRONT PAGE U.S. UK CANADA QUÉBEC FRANCE POLITICS 2012 BLOG HUFFPOST HILL 2012 ELECTIONS FUNDRACE GREEN POLLSTER SPECULATRON OFF THE BUS BUSINESS SMALL BUSINESS ENTERTAINMENT CELEBRITY ENTERTAINMENT MUSIC RADIO MOVIES TV GAMES COMEDY TECH TECH TECHCRUNCH JOYSTIQ SCIENCE ENGADGET APPLE BLOG MEDIA LIFE & STYLE STYLE NEWS STYLELIST FOOD NEWS WEDDINGS PARENTS GREEN TRAVEL STYLELIST HOME KITCHEN DAILY DIVORCE HUFF/POST50 RELIGION CULTURE ARTS PARENTS TRAVEL COLLEGE RELIGION IMPACT BOOKS EDUCATION COMEDY HEALTHY LIVING HEALTH AND FITNESS HEALTH NEWS MINDFUL LIVING SLEEP WOMEN HEALTHY LIVING PARENTS LOCAL NEW YORK SAN FRANCISCO DENVER MIAMI PATCH CHICAGO LOS ANGELES DC DETROIT YELLOW PAGES MORE GOOD NEWS SCIENCE BLACKVOICES SPORTS WORLD GAY VOICES GREEN LATINOVOICES COLLEGE CRIME WEIRD NEWS HIGH SCHOOL POLITICS POLLSTER ELECTION 2012 BLOG 2012 ELECTIONS 2012 TOOLBAR SPECULATRON HUFFPOST HILL FUNDRACE ELECTION DASHBOARD OFF THE BUS OCCUPY CPI Here is the original post: Steven Strauss: Chelsea Clinton for Congress? What Does That Tell Us About America? … Continue reading →

Posted in MS Treatment | Comments Off on Steven Strauss: Chelsea Clinton for Congress? What Does That Tell Us About America?

Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update

Posted: Published on February 27th, 2012

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA - News), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year. 2011 highlights include: Clinical and Regulatory Granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for Tovaxin® for the treatment of patients with Secondary Progressive Multiple Sclerosis (SPMS); Published the results of the Company’s prior Phase IIb TERMS clinical trial of Tovaxin in a leading peer-reviewed publication, Multiple Sclerosis Journal; Executed strategic agreements with the American Red Cross and the Blood Group Alliance, Inc. to streamline blood procurement for future clinical trials; and Met with Health Canada’s Biologics and Genetics Therapies Directorate as part of the process to secure approval for Opexa to conduct a portion of future clinical development in Canada. Operational Optimized the manufacturing process through the implementation of a functionally closed system and single cycle cGMP process; Advanced overall clinical plans for Tovaxin and clearly defined the study protocol for the planned Phase IIb clinical trial in SPMS; Increased employee headcount thereby strengthening our overall cell therapy expertise in preparation … Continue reading →

Posted in MS Treatment | Comments Off on Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update

Gilenya (Fingolimod): MS Drug Under Health Canada Review in Light of Serious Adverse Events

Posted: Published on February 27th, 2012

OTTAWA, ONTARIO--(Marketwire -02/27/12)- Health Canada is informing Canadians of an ongoing safety review of the multiple sclerosis (MS) drug Gilenya (the brand name for fingolimod). The review was initiated following reports of serious adverse events, including 11 deaths reported internationally. No deaths have been reported in Canada. Gilenya is a prescription drug authorized for the treatment of relapsing-remitting multiple sclerosis to reduce the frequency of attacks (relapses) and delay physical disability. Gilenya is generally recommended when other MS treatments have not been effective or cannot be tolerated. It was authorized in Canada in March 2011. Currently, it is not clear whether the deaths were caused by Gilenya or whether other factors may have played a role. Four of the 11 reports involved serious heart-related events (three involved heart attacks and one involved a disturbance of the heart rhythm), while the other seven are unexplained. Among these seven is a report involving a patient in the United States who died within 24 hours of taking the first dose. At the time of authorization, it was known that Gilenya can be associated with certain types of heart rhythm disturbances. The Canadian labelling contains several important warnings with respect to these risks. At … Continue reading →

Posted in MS Treatment | Comments Off on Gilenya (Fingolimod): MS Drug Under Health Canada Review in Light of Serious Adverse Events

Hollywood Reaches Out to Help Westfall Foundation Fight Neuromuscular Disease

Posted: Published on February 27th, 2012

Writer/Actors Jayce and Tiffany Bartok are very familiar with the damaging effects of the neuromuscular disease “Friedreichs Ataxia.” Jayce wrote and starred in the award-winning movie, “The Cake Eaters,” starring Kristen Stewart, which features Stewart playing the role of “Georgia” who has the disease “Friedreichs Ataxia.” This grabbed Kerry Westfall's attention. Wildomar, CA (PRWEB) February 26, 2012 CEO of the Westfall Foundation, Kerry Westfall, was born with a neuromuscular disease called Friedreichs Ataxia. Friedreich's Ataxia (also called FA or FRDA) is a rare inherited disease that causes nervous system damage and movement problems. It usually begins in childhood and leads to impaired muscle coordination (ataxia) that worsens over time. Although there is no effective treatment or cure available, Friedreich's ataxia patients and families have more and more reason for real hope. In fact, that hope has been translated into increasing confidence that treatment and a cure for Friedreich's ataxia will be achieved. When Kerry watched “The Cake Eaters,” he vowed to meet and personally thank the writer, Jayce Bartok. Kerry obtained Jayces email address and told him about his video, “Commit to Your Health," he was inspired, and, although he was currently very busy producing his newest film, "Tiny Dancer,” … Continue reading →

Comments Off on Hollywood Reaches Out to Help Westfall Foundation Fight Neuromuscular Disease

Stem cell find offers hope for infertility

Posted: Published on February 27th, 2012

Stem cell find offers hope for infertility By Lauran Neergard Monday, February 27, 2012 An experiment that produced human eggs from stem cells could one day be a boon for women who are desperate to have a baby, according to a study published yesterday. The work sweeps away the belief that a woman has only a limited stock of eggs and replaces it with the theory that the supply is continuously replenished from precursor cells in the ovary, its authors said. If the report is confirmed, harnessing those stem cells might one day lead to better treatments for women left infertile because of disease — or simply because they’re getting older. "Our current views of ovarian aging are incomplete. There’s much more to the story than simply the trickling away of a fixed pool of eggs," said lead researcher Jonathan Tilly of Harvard’s Massachusetts General Hospital, who had long hunted these cells in a series of studies. His previous work drew fierce scepticism. Independent experts urged caution about the latest findings. A key next step is to see whether other laboratories can verify the work. If so, then it would take years of additional research to learn how to use … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cell find offers hope for infertility

Seminar to focus on stem cell research development

Posted: Published on February 27th, 2012

The latest discoveries and promises of stem cell research and the development of new therapeutic approaches for a variety of diseases will be in focus at the Qatar International Conference on Stem Cell Science and Policy 2012 which begins today. The four-day event, being held at Qatar National Convention Centre, is a milestone in Qatar Foundation’s ongoing collaboration with the James A Baker III Institute for Public Policy at Rice University, Houston, Texas, US. The aim of QF’s joint initiative with the Baker Institute’s International Programme on Stem Cell Science Policy is to develop stem cell research in Qatar as well as to find ways to address the shared challenges of community support for stem cell research in Doha and Houston. To accomplish this goal, the programme has supported several events since its inception, including meetings, workshops, and training programmes in both cities. The conference, which brings together eminent international as well as regional scientists, ethicists and policymakers, will also present the developed policy options that account for cultural, ethical and religious factors. The event will draw attention to Qatar’s position in the development of stem cell research in the region and the world, given that research on stem cell … Continue reading →

Posted in Stem Cell Research | Comments Off on Seminar to focus on stem cell research development

Page 7,084«..1020..7,0837,0847,0857,086..7,0907,100..»